Young David 4

What Happened
David Young, President of Research & Development and a company director at Processa Pharmaceuticals (PCSA), reported a purchase of 2,531 shares on 2026-06-30. The transaction was reported as a purchase (code P) at $1.93 per share, for a total reported cost of $4,885. This was a buy (not a sale), which some investors view as a modest insider purchase rather than routine selling.

Key Details

• Transaction date: 2026-06-30; price: $1.93 per share; shares purchased: 2,531; total ≈ $4,885.
• Transaction type: Purchase (Form 4 code P — open-market or private purchase).
• Shares owned after transaction: Not specified in the filing.
• Footnotes/plan: No 10b5-1 plan, tax withholding, or other special footnotes reported.
• Filing: Form 4 was filed with the SEC on 2026-07-01 (appears to be filed the following business day).

Context
Insider purchases can be a useful datapoint for retail investors, but the size here is small relative to typical institutional or executive trades. No options were exercised and no shares were sold as part of this report. As always, use insider activity alongside company fundamentals and news when evaluating a position.